$PACK

Ranpak Holdings Corp (NYSE:PACK) Short Interest Down 36.4% in May

Ranpak Holdings Corp. (NYSE:PACK) saw short interest fall 36.4% in May, to 2,677,811 shares as of May 15 from 4,207,686 on April 30, according to the report. Short interest equals 3.4% of shares sold short, with a 2.8-day ratio. The company last reported Q1 EPS of -$0.12 and revenue of $101.2M.

Original reporting
Published Jun 3, 2026, 7:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 8:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Ranpak Holdings Corp (NYSE:PACK) Short Interest Down 36.4% in May — source image
Decision brief

The 30-second read

$PACKBullishMed
01

Why it matters

A 36.4% decline in short interest may reduce bearish positioning and dampen borrow-driven selling, but it does not by itself change Ranpak’s earnings power or near-term guidance.

02

Market read

Useful for flow/positioning traders to gauge whether bearish positioning is unwinding after the May short-interest update.

03

What to watch

The article doesn’t explain why shorts reduced exposure; traders should check whether the move coincided with earnings reaction, guidance changes, or broader risk-off/risk-on shifts.

Relevance 7/10Novelty 7/10Timing: pre-market today / positioning read-through after May short-interest print

Background

The piece is a short-interest update referencing May 15th versus April 30th, plus a snapshot of recent earnings (Apr 30) and institutional ownership changes.

Company-level read

Ticker impact

$PACKBullishMedium confidence
Context

Article reports Ranpak’s short interest fell 36.4% in May, with 3.4% of shares still sold short and a 2.8-day ratio.

Expected impact

Mildly bullish bias; expect limited follow-through unless paired with new earnings/guidance or demand signals.

Evidence & confidence

The datapoint is a positioning/flow metric (short interest) rather than operating performance; magnitude is meaningful but not typically a standalone driver.

Market effects

For packaging/industrial names, short-interest declines can signal improving sentiment but usually remain company-specific.

No explicit regional linkage beyond US-listed small/mid-cap flow.

Limited; short-interest data is primarily a US microstructure signal.

Counterpoint

Short interest can fall because shorts exit for reasons unrelated to fundamentals (liquidity, hedging changes), so price may not sustain.

Key entities

  • Ranpak Holdings Corp

    Subject of the short-interest decline and recent earnings snapshot.

  • Short interest (May 15 vs Apr 30)

    2,677,811 shares short on May 15, down 36.4% from 4,207,686 on Apr 30.

Related articles

$PACKMed

Ranpak Q2 Earnings Call Highlights

Ranpak (NYSE:PACK) reported Q2 results on an earnings call. Management said constant-currency net revenue rose 15.4% in Europe and Asia-Pacific, with automation revenue up 103.7% and PPS volumes up 2.4% YoY. Adjusted EBITDA increased $2.6M to $19.1M; gross margin improved 150 bps. Ranpak expects automation adjusted EBITDA breakeven late 2026 and EBITDA-positive in 2027.

$PACKMed

Ranpak Holdings Corp. (PACK): Results of Operations and Financial Condition

Ranpak Holdings Corp. (PACK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a04pack-202606xex99x1.htm EX-99.1 Document Exhibit 99.1 Ranpak Holdings Corp. Reports Second Quarter 2026 Financial Results • Net revenue for the second quarter increased 14.0% year over year to $105.2 million and increased 12.2% year over year on a constant currency ba

$PACKMedAI 8/10

Ranpak (NYSE:PACK) Reaches New 1

Ranpak Holdings (NYSE:PACK) hit a new 52-week high on Tuesday, trading up to $6.67 and last at $6.62 versus a prior close of $6.28. The article cites recent analyst actions including UBS and Cantor reiterating “overweight,” while Wall Street Zen raised PACK to “hold.” MarketBeat shows a “Moderate Buy” consensus and $6.83 target. In its April 30 earnings, Ranpak reported EPS of -$0.12 and revenue of $101.2M.

$MRKHighAI 9/10

StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too

Merck (MRK) and Moderna (MRNA) announced positive Phase III results for their cancer vaccine, intismeran, showing improved outcomes when combined with Keytruda. Shares of both companies surged, with Moderna gaining 130.5% over three days. Sequencing companies like Illumina (ILMN) and PacBio (PACB) also saw gains due to the personalized nature of the therapy. Analysts upgraded Moderna's stock, citing broadened sales potential, while others remained cautious about long-term expectations.

$BAMedAI 8/10

Boeing’s MAX 10 Schedule Puts 27 United Planes Beyond 2027 as Labor Tensions Rise

Boeing's MAX 10 delays push 27 United Airlines jets to post-2027 delivery, per United's latest filing. Boeing completed flight tests but awaits certification. BA shares fell 7.5% last week, erasing $13.8B in market cap. Labor tensions rise as Boeing engineers reject contract offers, risking a strike. Boeing's Q2 revenue rose 8% to $24.56B, with a $715B backlog. Analysts maintain a positive outlook, with a consensus price target of $274.85.

$TEVAMed

Teva share price hits nearly 10-year high

Teva Pharmaceutical (TEVA) reached a nearly 10-year high, with shares up 1.44% on Friday, giving a $43.51B market cap. The company reported strong Q2 results, raised annual revenue guidance, and received debt rating upgrades from Moody's and Fitch. The FDA accepted its Ecopipam drug application. Analysts have an average price target of $42.38, a 12.3% premium to current levels.